The results of our study show that CLE has an antioxidant activity that is inferior by 79-fold to ascorbic acid, and an AChE inhibitory activity 131-fold less than Rivastigmine, a known AChE inhibitory drug being prescribed to AD patients. The gene discussed is ACHE; the disease is Alzheimer disease.